We recently published a list of 15 Best Fast Growth Stocks To Buy Right Now. In this article, we are going to take a look at where Sarepta Therapeutics, Inc.

The evolution of cell and gene therapy is reshaping drug discovery, providing new hope for rare diseases and cancer through innovative gene editing approaches.

Solid Biosciences’ gene therapy uses a shortened version of the dystrophin protein, which is engineered to mimic the key functions of full-length dystrophin and allows it be delivered more effectively ...

The cuts hit the FDA’s medical device center particularly hard, impacting product reviewers and researchers of AI-enabled ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...

The Duchenne muscular dystrophy (DMD) market is projected to grow from $2.3 billion in 2023 to $5.2 billion in 2033 across seven major markets, driven by recent approvals of novel therapies, says ...

UBS has upgraded Roche ( OTCQX:RHHBY) to buy from neutral, citing the company's growth outlook. "We see sustained outperformance of Vabysmo and Ocrevus as key drivers of near-term growth, with ...

State of Alaska Department of Revenue reduced its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 1.3% ...

Equities research analysts at Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) in a research report issued on Tuesday, MarketBeat ...

Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...